Your session is about to expire
← Back to Search
PF-06651600 for Alopecia Areata (ALLEGRO-LT Trial)
ALLEGRO-LT Trial Summary
This trial is testing a new drug to treat alopecia areata, which is an autoimmune disease that causes hair loss. The trial is open-label, which means all patients will receive the active drug. There is also a sub-study evaluating the immune response to vaccines in patients who have received the drug for at least 6 months.
ALLEGRO-LT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowALLEGRO-LT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 460 Patients • NCT04413617ALLEGRO-LT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Are people with the qualifying condition still being accepted into this trial?
"Although this study is no longer recruiting patients, it was active from July 18th, 2019 to September 22nd, 2020. If you are seeking other studies, there are 93 clinical trials for alopecia areata and 22 for PF-06651600 that are currently looking for participants."
Has the FDA cleared PF-06651600 for use?
"There is already some efficacy data for PF-06651600, as well as multiple rounds of safety testing data, so it received a score of 3."
Are there other similar drugs to PF-06651600 that have undergone clinical trials?
"PF-06651600 was first researched in 2013 at The Rockefeller University. So far, there have been 149 completed studies with 22 more currently recruiting participants. Verona, New jersey is home to many of these ongoing trials."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
What site did they apply to?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger